Pharmaceutical manufacturers need to make patient support programs more effective
The industry invests $5B annually developing patient resources and support programs, but 20 to 30 percent of patients never start the prescribed therapy. For those who do, about half stop taking their medications as directed by month six.
Driving program effectiveness and efficiency with AI-powered personalization
Artificial intelligence can personalize the patient experience to drive each individual’s next-best-action using identified data. By personalizing interventions on an individual level, organizations can make informed, strategic decisions to deliver better health outcomes.
Top pharmaceutical companies see positive results using AI
AI-powered personalization works and is applicable for practically all therapeutic areas. For example, a depressive disorder medication saw a nine percent increase in therapy initiation rates and an immunology biologic therapy saw a 14 percent increase in days on therapy.
Download the infographic to see highlights.